Conjunctivitis Clinical Trial
Official title:
A Comparison of the Sensitivity and Specificity of the RPS Adeno Detector IV™ at Detecting the Presence of Adenovirus to Viral Cell Culture.
To engage in a multi-center, prospective, masked clinical trial to investigate a non-invasive, rapid diagnostic test, the RPS Adeno Detector IV's ability to detect the presence of the adenovirus (ADV) antigen in cases of acute conjunctivitis by comparing it to cell culture with confirmatory immunofluorescence (CC-IFA). The polymerase chain reaction (PCR) will be used as a referee for discrepant cases.
The RPS Adeno Detector IV will show substantial equivalence to cell culture for diagnosing adenoviral conjunctivitis. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00783198 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
|
Phase 2/Phase 3 | |
Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
Recruiting |
NCT06229379 -
The Effects of a Large Language Model on Clinical Questioning Skills
|
N/A | |
Not yet recruiting |
NCT03631108 -
Feasibility Study and Preliminary Application Study on Iris OCTA
|
||
Completed |
NCT01028027 -
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
|
Phase 3 | |
Completed |
NCT00978029 -
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
|
Phase 2 | |
Completed |
NCT00550550 -
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00562159 -
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
|
Phase 3 | |
Withdrawn |
NCT02795273 -
Efficacy and Safety of Grass-SPIRE Registration Study
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT01600365 -
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
|
Phase 3 | |
Completed |
NCT00567918 -
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
|
Phase 3 | |
Completed |
NCT04374656 -
Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Completed |
NCT02472223 -
Reducing Adenoviral Patient Infected Days
|
N/A | |
Completed |
NCT00001734 -
Screening for NEI Clinical Studies
|
N/A | |
Completed |
NCT00623701 -
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
|
Phase 3 | |
Completed |
NCT00581542 -
Moxifloxacin vs. Polytrim for Conjunctivitis
|
Phase 4 | |
Completed |
NCT04287608 -
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
|
||
Completed |
NCT04984941 -
Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
|
||
Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 |